Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21205127 | 0.75 | CYP1A2 (0.35) | KCNH2CYP1A2GRM5 | |
| SCHEMBL21163708 | 0.75 | RET (0.34) | KCNH2CYP1A2GRM5 | |
| SCHEMBL22605599 | 0.75 | RET (0.34) | KCNH2CYP1A2GRM5 | |
| SCHEMBL24975582 | 0.75 | RET (0.34) | KCNH2CYP1A2GRM5 | |
| SCHEMBL11698200 | 0.74 | KMT2A (0.41) | KDM4EALDH1A1POLB | |
| SCHEMBL1813384 | 0.73 | ALDH1A1 (0.36) | CTSKKDM4EALDH1A1MAPK1CYP1A2 | |
| SCHEMBL5236933 | 0.73 | ALDH1A1 (0.36) | CTSKKDM4EALDH1A1MAPK1CYP1A2 | |
| SCHEMBL31735560 | 0.68 | CHEK1 (0.36) | KDM4EALDH1A1MAPK1CYP1A2POLB | |
| SCHEMBL22605608 | 0.68 | LMNA (0.42) | KDM4EALDH1A1CYP1A2GRM5 | |
| SCHEMBL31735859 | 0.67 | PKM (0.38) | KDM4EALDH1A1POLBPKMCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | CTSK 3291/4885KDM4E 1721/4885ALDH1A1 329/4885 |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | CTSK 3291/4885KDM4E 1721/4885ALDH1A1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.